At the request of Congress, in 2008 NIH began releasing to the public how much the agency spends in various research categories. I decided to pick out the top-funded disease areas to get a sense of what disorders and diseases the U.S. government is prioritizing. The red and green arrows indicate whether categories had a decrease or bump in funding from the previous year, respectively.
In an era of massive clinical trial failures and R&D cutbacks in Big Pharma, drug developers are searching for ways to test drug candidates more accurately and cost-efficiently before pouring millions of dollars into clinical trials. New technology like organs-on-chips and bioprinted tissues have the potential to test the safety of drugs more effectively for a myriad of diseases.
Organizations from both the private sector and academia are working on such technology to help drug developers advance new therapies toward FDA approval.
FierceBiotech is now available on iPhone and iPad!
This is the best FierceBiotech reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Android users: We're on track to have an app complete by the end of the year.
Have something to say? Join the conversation at
FierceBiotech's LinkedIn group.
POPULAR COMMENT THREADS
Injecting a gene directly into the heart may be able to replace the need for an electronic pacemaker, according to new research by scientists at the Cedars-Sinai Heart Institute.
A new discovery of an ancestral fossil virus buried within everyone's genomes might provide the key to eradicating HIV.
An in vitro technique using samples of beating heart tissue may be able to test the effects of drugs on the heart without unnecessary testing on humans or animals, according to new research.
Much of Alzheimer's drug research has focused on targeting amyloid beta, a protein long thought to be toxic when it clumps together to form plaques in the brain.
Startup Neurotrope is teaming up with the Icahn School of Medicine at Mount Sinai in New York City to further develop its bryostatins for the treatment of Niemann-Pick disease type C, a rare disease that mostly affects children.
The U.S. Centers for Disease Control and Prevention reports that the first locally acquired case of chikungunya, a mosquito-borne virus that causes symptoms similar to those of dengue fever, has surfaced in the U.S. in Florida.
From Our Sister Sites
Shares of Puma Biotechnology soared more than 220% after the markets closed on Tuesday as investors cheered the biotech's positive Phase III numbers for a late-stage study of their lead drug neratinib (PB272).
Amid growing safety concerns over the use of power morcellator tools in gynecological procedures, new research shows that a significant number of women undergoing laparoscopic surgery with the device have increased levels of undetected cancer.